<DOC>
	<DOCNO>NCT00131261</DOCNO>
	<brief_summary>The purpose open-label , non-randomized trial ass safety effectiveness PXD101 , alone combination dexamethasone , patient advance multiple myeloma . PXD101 new , potent histone deacetylase ( HDAC ) inhibitor . Various member class drug show activity preclinical study initial clinical trial multiple myeloma lymphoma . Furthermore , HDAC inhibitor , include PXD101 , show sensitize myeloma cell kill effect chemotherapeutic agent , include dexamethasone , well-established agent relapse myeloma .</brief_summary>
	<brief_title>Clinical Trial PXD101 Patients With Advanced Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<criteria>Inclusion criterion 1 . Signed informed consent 2 . A confirmed diagnosis multiple myeloma , diagnostic criterion follow , patient fail least two prior line therapy . Diagnostic criterion multiple myeloma : A Monoclonal immunoglobulin ( Mcomponent ) serum IgGtype &gt; 30 g/l , IgA type &gt; 20 g/l , IgD type IgE type concentration and/or excretion Mcomponent urine type k l type &gt; 1 g/24 hour . B Mcomponent serum and/or urine low concentration indicate ' A ' . C 10 % plasma cell bone marrow aspirate plasmocytosis biopsy bone marrow soft tissue tumor D Osteolytical bone lesion . The diagnosis multiple myeloma demand one follow combination : A+C , A+D , B+C+D . 3 . Evaluable disease ( define ) 4 . Adequate bone marrow hepatic function include follow : 1 . WBC &gt; 2.5 x 109/l , absolute neutrophil count ≥ 1.5 x 109/l , platelet ≥ 50x109/l 2 . Total bilirubin ≤1.5 x upper normal limit . 3 . AST ( SGOT ) , ALT ( SGPT ) ≤2.5 x upper normal limit 5 . Serum potassium within normal range . 6 . Age ≥18 year 7 . Performance status ( PS ) ≤2 ( ECOG scale ) 8 . Estimated life expectancy great 3 month 9 . Female patient reproductive potential negative serum pregnancy test within last 7 day trial enrollment use safe contraceptive period 60 day trial . Fertile female partner male participant must likewise use contraceptive . Exclusion criteria 1 . Anticancer therapy include chemotherapy , radiotherapy , endocrine therapy , immunotherapy use investigational agent within last 4 week long period depend defined characteristic agent use ( e.g . 6 week mitomycin nitrosourea ) . Exception : bisphosphonates bone disease cause multiple myeloma . 2 . Active infection medical condition likely interfere trial procedure . 3 . Significant cardiovascular disease include unstable angina pectoris , uncontrolled hypertension , congestive heart failure relate primary cardiac disease , condition require antiarrhythmic therapy , ischemic severe valvular heart disease , myocardial infarction within 6 month prior trial entry . 4 . A marked baseline prolongation QT/QTc interval , e.g. , repeat demonstration QTc interval &gt; 500 ; Long QT Syndrome ; require use concomitant medication PXD101 infusion day may cause Torsade de Pointes . ( See Appendix B list ) . 5 . Patients renal insufficiency define calculated creatinine clearance &lt; 45 ml/min . 6 . Clinically significant central nervous system disorder require neuroleptic anticonvulsant medication . 7 . Altered mental status preclude understand informed consent process and/or completion necessary study 8 . Other malignant disease require treatment 9 . Nonsecretory multiple myeloma symptomatic amyloidosis 10 . Pregnant breastfeed woman 11 . Women childbearing age potential , use effective contraception 12 . Known HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Neoplasms</keyword>
</DOC>